Shares of global orthopaedic device company
Wright Medical Group, Inc.
) reached new 52-week high of $30.87 in mid-day trading on Dec
31. Shares of the company closed at $30.71 on the same day,
representing a strong one-year return of 46.3%.
ADVAXIS INC (ADXS): Get Free Report
DIADEXUS INC (DDXS): Get Free Report
HILL-ROM HLDGS (HRC): Free Stock Analysis
WRIGHT MEDICAL (WMGI): Free Stock Analysis
To read this article on Zacks.com click here.
WMGI has a market cap of $1.45 billion. Average volume of shares
traded over the last three months stood at approximately 424.9K.
Shares of Wright Medical Group started rising following
completion of acquisition of French orthopedic extremities
company Biotech International on Nov 15. The acquisition will add
Biotech's extremity product portfolio that will boost WMGI's
global Extremities business growth.
The acquisition was initially announced on Oct 16, 2013 and
involved an upfront payment of roughly $75 million in cash and
stock. It also includes additional payments of up to $5 million
in cash, payable upon attaining certain revenue milestones in
2014 and 2015.
However, Wright Medical failed to impress investors in its third
quarter results. The company posted a broader loss of $8.2
million or 18 cents per share for the quarter compared with $1.6
million or 4 cents in the same quarter of 2012. However, earnings
met the Zacks Consensus Estimate.
Reported net loss was $124.5 million or $2.68 per share, compared
with $4.1 million or 11 cents in the third quarter of 2012. Net
revenues increased 13.3% (14% in constant currency) to $57.6
million during the quarter, exceeding the Zacks Consensus
Estimate of $56.0 million.
While announcing the quarterly results, WMGI narrowed its revenue
guidance for 2013 to $237-$240 million from $235-$240 million,
which has incorporated short-term dis-synergies due to the
previously announced transaction with MicroPort. The Zacks
Consensus Estimate of $239 million for the year lies within the
However, Wright Medical reiterated its 2013 adjusted earnings per
share guidance of a loss of 55 to 59 cents, based on
approximately 45.3 million shares outstanding. The Zacks
Consensus Estimate of a loss of 57 cents for the year lies within
the guided range.
Due to the acquisition of Biotech, WMGI now expects full year
revenues towards the high-end of the guided range. However, the
company kept its adjusted earnings per share guidance unchanged.
Currently, Wright Medical retains a Zacks Rank #4 (Sell). Some
better-ranked stocks in the medical product industry include
Hill-Rom Holdings, Inc.
). All of them carry a Zacks Rank #2 (Buy).